EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
    1.3.1.10 | Chronic Periodontitis |
29400320 |
Structural characterization of Porphyromonas gingivalis enoyl-ACP reductase II (FabK). |
causal interaction
therapeutic application
unassigned |
1
1
0 |
| 1.3.1.10 | Clostridium Infections |
30501172 |
The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection. |
therapeutic application
unassigned |
1
0 |
| 1.3.1.10 | Cysts |
14623959 |
Delivery of antimicrobials into parasites. |
ongoing research
unassigned |
2
0 |
| 1.3.1.10 | Dental Plaque |
17110966 |
Triclosan inhibition of membrane enzymes and glycolysis of Streptococcus mutans in suspensions and biofilms. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
| 1.3.1.10 | Infections |
12010964 |
Mycobacterium tuberculosis genes induced during infection of human macrophages. |
ongoing research
unassigned |
4
0 |
| 1.3.1.10 | Infections |
19282328 |
Vinaxanthone, a new FabI inhibitor from Penicillium sp. |
causal interaction
therapeutic application
unassigned |
2
4
0 |
| 1.3.1.10 | Infections |
19734171 |
Substituted diphenyl ethers as a broad-spectrum platform for the development of chemotherapeutics for the treatment of tularaemia. |
therapeutic application
unassigned |
3
0 |
| 1.3.1.10 | Infections |
23144254 |
The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection. |
causal interaction
unassigned |
2
0 |
| 1.3.1.10 | Infections |
23398677 |
Design, synthesis, structural characterization by IR, (1) H, (13) C, (15) N, 2D-NMR, X-ray diffraction and evaluation of a new class of Phenylaminoacetic acid benzylidene hydrazines as pfENR inhibitors. |
therapeutic application
unassigned |
1
0 |
| 1.3.1.10 | Infections |
23433442 |
Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. |
therapeutic application
unassigned |
4
0 |
